#AS­CO21: Ahead of Au­gust PDU­FA date, Astel­las and Seagen sweet­en Pad­cev pitch with new da­ta

Astel­las and Seagen made waves back in 2019 when they nabbed con­di­tion­al ap­proval for their Nectin-4 tar­get­ing ther­a­py Pad­cev in urothe­lial can­cer. Now, as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER